(Q34430205)

2 August 2017

title

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer (English)

1 reference

2 August 2017

main subject

phase III clinical trial

0 references

0 references

1 reference

randomized experiment

1 reference

inferred from title

head and neck carcinoma

1 reference

21

Everett E Vokes

1 reference

2 August 2017

20

Daniel J Haraf

1 reference

2 August 2017

18

Tanguy Y Seiwert

1 reference

2 August 2017

1

Ezra E W Cohen

1 reference

2 August 2017

9

Bharat B Mittal

1 reference

2 August 2017

7

Bruce E Brockstein

1 reference

2 August 2017

3

Masha Kocherginsky

1 reference

2 August 2017

19

Victoria M Villaflor

1 reference

2 August 2017

Theodore G Karrison

2

1 reference

2 August 2017

Jeffrey Mueller

4

1 reference

2 August 2017

Robyn Egan

5

1 reference

2 August 2017

Chao H Huang

6

1 reference

2 August 2017

Mark B Agulnik

8

1 reference

2 August 2017

Furhan Yunus

10

1 reference

2 August 2017

Sandeep Samant

11

1 reference

2 August 2017

Luis E Raez

12

1 reference

2 August 2017

Ranee Mehra

13

1 reference

2 August 2017

Priya Kumar

14

1 reference

2 August 2017

Frank Ondrey

15

1 reference

2 August 2017

Patrice Marchand

16

1 reference

2 August 2017

Bettina Braegas

17

1 reference

2 August 2017

language of work or name

English

0 references

publication date

21 July 2014

1 reference

Journal of Clinical Oncology

2 August 2017

published in

1 reference

2 August 2017

volume

32

1 reference

2 August 2017

issue

25

1 reference

2 August 2017

page(s)

2735-2743

1 reference

Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.

2 August 2017

uses

randomized experiment

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Multidisciplinary care of the patient with head and neck cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Imputing missing covariate values for the Cox model

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

A Multiple Testing Procedure for Clinical Trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Sample-size formula for the proportional-hazards regression model

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4876357

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck

27 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25049329

12 December 2020

inferred from PubMed ID database lookup

Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25049329

12 December 2020

inferred from PubMed ID database lookup

A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25049329

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.2013.54.6309

1 reference

2 August 2017

1 reference

2 August 2017

1 reference